IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation

Qianghua Xu, Yoshinori Katakura, Makiko Yamashita, Shengguo Fang, Takashi Tamura, Shin Ei Matsumoto, Yoshihiro Aiba, Kiichiro Teruya, Kazuhiro Osada, Ryuhei Nishikawa, Sanetaka Shirahata

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.

Original languageEnglish
Pages (from-to)2279-2284
Number of pages6
JournalBioscience, Biotechnology and Biochemistry
Volume68
Issue number11
DOIs
Publication statusPublished - Nov 1 2004

Fingerprint

Th2 Cells
Lymphocytes
Immunization
antibody formation
interleukin-10
Antibodies
Interleukin-10
B-lymphocytes
Antibody Formation
Antigens
B-Lymphocytes
lymphocytes
Cells
immunization
leucylleucine
T-cells
cytokines
Cytokines
antigens
Esters

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Analytical Chemistry
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Organic Chemistry

Cite this

IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation. / Xu, Qianghua; Katakura, Yoshinori; Yamashita, Makiko; Fang, Shengguo; Tamura, Takashi; Matsumoto, Shin Ei; Aiba, Yoshihiro; Teruya, Kiichiro; Osada, Kazuhiro; Nishikawa, Ryuhei; Shirahata, Sanetaka.

In: Bioscience, Biotechnology and Biochemistry, Vol. 68, No. 11, 01.11.2004, p. 2279-2284.

Research output: Contribution to journalArticle

Xu, Qianghua ; Katakura, Yoshinori ; Yamashita, Makiko ; Fang, Shengguo ; Tamura, Takashi ; Matsumoto, Shin Ei ; Aiba, Yoshihiro ; Teruya, Kiichiro ; Osada, Kazuhiro ; Nishikawa, Ryuhei ; Shirahata, Sanetaka. / IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation. In: Bioscience, Biotechnology and Biochemistry. 2004 ; Vol. 68, No. 11. pp. 2279-2284.
@article{007747c1de7e4786a90eb1262c36f3d9,
title = "IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation",
abstract = "An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.",
author = "Qianghua Xu and Yoshinori Katakura and Makiko Yamashita and Shengguo Fang and Takashi Tamura and Matsumoto, {Shin Ei} and Yoshihiro Aiba and Kiichiro Teruya and Kazuhiro Osada and Ryuhei Nishikawa and Sanetaka Shirahata",
year = "2004",
month = "11",
day = "1",
doi = "10.1271/bbb.68.2279",
language = "English",
volume = "68",
pages = "2279--2284",
journal = "Bioscience, Biotechnology and Biochemistry",
issn = "0916-8451",
publisher = "Japan Society for Bioscience Biotechnology and Agrochemistry",
number = "11",

}

TY - JOUR

T1 - IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation

AU - Xu, Qianghua

AU - Katakura, Yoshinori

AU - Yamashita, Makiko

AU - Fang, Shengguo

AU - Tamura, Takashi

AU - Matsumoto, Shin Ei

AU - Aiba, Yoshihiro

AU - Teruya, Kiichiro

AU - Osada, Kazuhiro

AU - Nishikawa, Ryuhei

AU - Shirahata, Sanetaka

PY - 2004/11/1

Y1 - 2004/11/1

N2 - An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.

AB - An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.

UR - http://www.scopus.com/inward/record.url?scp=19944379794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944379794&partnerID=8YFLogxK

U2 - 10.1271/bbb.68.2279

DO - 10.1271/bbb.68.2279

M3 - Article

C2 - 15564665

AN - SCOPUS:19944379794

VL - 68

SP - 2279

EP - 2284

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

SN - 0916-8451

IS - 11

ER -